Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until September, 2020.

  1. In Vivo Studies of a Novel HDAC Inhibitor for Treating Hemoglobin Disorders

    SBC: Cetya Therapeutics, Inc.            Topic: NHLBI

    PROJECT SUMMARY Thehemoglobinopathies are prevalent genetic blood diseases with few treatment optionsIt is estimate thatof the worldandapos s population carries an abnormal hemoglobin gene withinfants born annually with a severe life threatening hemoglobinopathyDrug mediated induction of normalbut developmentally silencedfetal hemoglobinHbFexpression reduces anemia and ameliorates clinical severit ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Non-Invasive Physiologic Evaluation of Peripheral Arterial Disease

    SBC: RFPi, Inc.            Topic: NHLBI

    ABSTRACT Peripheral Arterial DiseasePADis a substantial healthcare burden in the USestimated andgtMand around the worldestimated andgtMIn the aging populationoverwith age andgtyears have PADof all patients with PAD are asymptomaticand up toof the remaining patients have atypical symptomsThe conventional ankle brachial indexcABIratio is established as the initial diagnostic evaluation in symptomati ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Ultrasound-Based Device to Guide Treatment of Graft-Versus-Host-Disease using Skin Elasticity as a Biomarker

    SBC: Microelastic Ultrasound Systems, Inc.            Topic: NCI

    Ultrasound Based Device to Guide Treatment of Graft Versus Host Disease using Skin Elasticity as a BiomarkerABSTRACT Sclerotic chronic graft versus host diseasecGVHDdevelops inof allogenic Human Stem Cell TransplantHCTrecipients and is associated with significant morbidity and mortalityGVHD is treated with immunosuppressionwhich puts patients at severe risk of infectionImmunosuppression must there ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Development of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating multi-drug resistant bacteremia

    SBC: Arrevus, Inc.            Topic: NIAID

    Bloodstream infectionsBSIscaused by Gram negative bacterial pathogens are associated with significant morbidity and mortality due to the antibiotic resistant nature of the pathogensInfections caused by multi drug resistantMDRbacterial pathogens result in substantial health and economic impact due to the lack of effective therapeutic optionsThis lack of treatment options is particularly relevant fo ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Personalized Neural Stem Cell Therapy for Cancer

    SBC: Falcon Therapeutics, Inc.            Topic: NCATS

    PROJECT SUMMARY GlioblastomaGBMis an intractable cancer with an average survival time oftomonthsTreatment options are limited by the infiltration of tumor cells into healthy tissue and the difficulty of delivering effective chemotherapeutics across the blood brain barrierbut engineered neural stem cellsNSCshold great promise as GBM therapies because they selectively migrate to tumor cells and can ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Developing a Small Peptide to Control Autoimmune Inflammation In Type 1 Diabetes

    SBC: Op-T-Mune, Inc            Topic: NIAID

    TypeDiabetesT Daffects an ever growing populationWhile this disease typically has been associated with juvenilesthe disease in adult populations is rapidly increasingThe defining clinical component is insulin losswhich occurs because of sustained inflammation in the isletsAt present there is no means to prevent or reverse insulin lossA major inflammatory pathway in T D that contributes to insulin ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Enzymatic synthesis of heparin sulfate and chondroitin sulfate

    SBC: Glycan Therapeutics LLC            Topic: 300

    Abstract This fast track STTR application proposes to synthesize structurally defined heparan sulfate and chondroitin sulfate oligosaccharides for biological researchGlycan Therapeutics is a biotech company specializing sulfated carbohydrates using innovative enzyme based methodsThis proposal is focused on the synthesis of large authentic oligosaccharides in the size range ofmers tomersas well as ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a Clinical Screening Platform for Type 1 Diabetes

    SBC: Op-T-Mune, Inc            Topic: NIDDK

    AbstractA major shortfall in clinical care for diabetes is a rapid and accurate screen for progression to diseaseCurrent criteria involve HLA haplotypeand the presence of auto antibodiesAAGenome wide associated studiesGWASrevealed only immune associated genes including HLA as T D predictorsThe ability to differentiate from other diseases was very limitedPre typediabetesp T Dis now being identified ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Scientific Merit and Feasibility of Fructokinase Inhibition for Obesity

    SBC: Colorado Research Partners LLC            Topic: 300

    Our goal is to develop a firstin class therapeutic agent that directly blocks the metabolism of fructosea key component in sugarIntake of sugarsucroseand high fructose corn syrupHFCSinduces metabolic syndrome and diabetes in laboratory animals and are strongly associated with obesity and diabetes in humansBoth sucrose and HFCS contain fructosewhich stimulates food intake by inducing leptin resista ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  10. HLS- Cyclic CAR peptide: a targeted therapy for pulmonary hypertension

    SBC: VASCULAR BIOSCIENCES, INC.            Topic: NHLBI

    PUBLIC ABSTRACT This projectin response to announcement HLSdescribes a development program for CARSKNKDCCARa synthetic cyclic peptide that selectively targets diseased pulmonary vascular endothelium and enhances the therapeutic effect of vasodilator therapiesfor the treatment of pulmonary hypertensionPHPH is a disorder of elevated pulmonary vascular resistance characterized by progressive thickeni ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government